610 related articles for article (PubMed ID: 25744437)
1. BRAF V600E mutation-specific antibody: A review.
Ritterhouse LL; Barletta JA
Semin Diagn Pathol; 2015 Sep; 32(5):400-8. PubMed ID: 25744437
[TBL] [Abstract][Full Text] [Related]
2. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
3. BRAF V600 mutation detection in melanoma: a comparison of two laboratory testing methods.
O'Brien O; Lyons T; Murphy S; Feeley L; Power D; Heffron CCBB
J Clin Pathol; 2017 Nov; 70(11):935-940. PubMed ID: 28424234
[TBL] [Abstract][Full Text] [Related]
4. Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody.
Capper D; Preusser M; Habel A; Sahm F; Ackermann U; Schindler G; Pusch S; Mechtersheimer G; Zentgraf H; von Deimling A
Acta Neuropathol; 2011 Jul; 122(1):11-9. PubMed ID: 21638088
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
6. BRAF-V600 Mutation Heterogeneity in Primary and Metastatic Melanoma: A Study With Pyrosequencing and Immunohistochemistry.
Yaman B; Kandiloğlu G; Akalin T
Am J Dermatopathol; 2016 Feb; 38(2):113-20. PubMed ID: 26630683
[TBL] [Abstract][Full Text] [Related]
7. Intrapatient homogeneity of BRAFV600E expression in melanoma.
Menzies AM; Lum T; Wilmott JS; Hyman J; Kefford RF; Thompson JF; O'Toole S; Long GV; Scolyer RA
Am J Surg Pathol; 2014 Mar; 38(3):377-82. PubMed ID: 24335665
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemical analysis of BRAF(V600E) expression of primary and metastatic melanoma and comparison with mutation status and melanocyte differentiation antigens of metastatic lesions.
Busam KJ; Hedvat C; Pulitzer M; von Deimling A; Jungbluth AA
Am J Surg Pathol; 2013 Mar; 37(3):413-20. PubMed ID: 23211290
[TBL] [Abstract][Full Text] [Related]
9. Assessment of BRAF V600E Status in Colorectal Carcinoma: Tissue-Specific Discordances between Immunohistochemistry and Sequencing.
Estrella JS; Tetzlaff MT; Bassett RL; Patel KP; Williams MD; Curry JL; Rashid A; Hamilton SR; Broaddus RR
Mol Cancer Ther; 2015 Dec; 14(12):2887-95. PubMed ID: 26438153
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of TERT promoter mutations and ALK rearrangement in thyroid cancer patients with a high prevalence of the BRAF V600E mutation.
Bae JS; Kim Y; Jeon S; Kim SH; Kim TJ; Lee S; Kim MH; Lim DJ; Lee YS; Jung CK
Diagn Pathol; 2016 Feb; 11():21. PubMed ID: 26857243
[TBL] [Abstract][Full Text] [Related]
11. Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.
Behling F; Barrantes-Freer A; Skardelly M; Nieser M; Christians A; Stockhammer F; Rohde V; Tatagiba M; Hartmann C; Stadelmann C; Schittenhelm J
Diagn Pathol; 2016 Jun; 11(1):55. PubMed ID: 27350555
[TBL] [Abstract][Full Text] [Related]
12. Lymph node metastases of melanoma: challenges for BRAF mutation detection.
Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT
Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393
[TBL] [Abstract][Full Text] [Related]
13. Clinical significance of BRAF V600E mutational status in capsular nevi of sentinel lymph nodes in patients with primary cutaneous melanoma.
Siroy AE; Aung PP; Torres-Cabala CA; Tetzlaff MT; Nagarajan P; Milton DR; Curry JL; Ivan D; Prieto VG
Hum Pathol; 2017 Jan; 59():48-54. PubMed ID: 27666765
[TBL] [Abstract][Full Text] [Related]
14. Immunohistochemistry as a reliable method for detection of BRAF-V600E mutation in melanoma: a systematic review and meta-analysis of current published literature.
Anwar MA; Murad F; Dawson E; Abd Elmageed ZY; Tsumagari K; Kandil E
J Surg Res; 2016 Jun; 203(2):407-15. PubMed ID: 27363650
[TBL] [Abstract][Full Text] [Related]
15. Immunohistochemistry using the BRAF V600E mutation-specific monoclonal antibody VE1 is not a useful surrogate for genotyping in colorectal adenocarcinoma.
Adackapara CA; Sholl LM; Barletta JA; Hornick JL
Histopathology; 2013 Aug; 63(2):187-93. PubMed ID: 23763264
[TBL] [Abstract][Full Text] [Related]
16. Cytomorphologic features in thyroid nodules read as "suspicious for malignancy" on cytology may predict thyroid cancers with the BRAF mutation.
Kwon HJ; Kim EK; Kwak JY
Pathol Res Pract; 2015 Sep; 211(9):671-6. PubMed ID: 26187369
[TBL] [Abstract][Full Text] [Related]
17. Immunohistochemistry with the anti-BRAF V600E (VE1) antibody: impact of pre-analytical conditions and concordance with DNA sequencing in colorectal and papillary thyroid carcinoma.
Dvorak K; Aggeler B; Palting J; McKelvie P; Ruszkiewicz A; Waring P
Pathology; 2014 Oct; 46(6):509-17. PubMed ID: 25014730
[TBL] [Abstract][Full Text] [Related]
18. Detection of the BRAF V600E mutation in colon carcinoma: critical evaluation of the imunohistochemical approach.
Lasota J; Kowalik A; Wasag B; Wang ZF; Felisiak-Golabek A; Coates T; Kopczynski J; Gozdz S; Miettinen M
Am J Surg Pathol; 2014 Sep; 38(9):1235-41. PubMed ID: 24832158
[TBL] [Abstract][Full Text] [Related]
19. VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.
Na JI; Kim JH; Kim HJ; Kim HK; Moon KS; Lee JS; Lee JH; Lee KH; Park JT
Virchows Arch; 2015 Aug; 467(2):155-68. PubMed ID: 25894433
[TBL] [Abstract][Full Text] [Related]
20. Microfluidic-Based Immunohistochemistry Combined With Next-Generation Sequencing on Diagnostic Tissue Sections for Detection of Tumoral BRAF V600E Mutation.
Leblond AL; Rechsteiner M; Jones A; Brajkovic S; Dupouy D; Soltermann A
Am J Clin Pathol; 2019 Jun; 152(1):59-73. PubMed ID: 31065676
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
